Teniposide

General Toxicity Notes
Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
Excreted Unchanged %
4-14
Half-Life (Normalesrd) Hours
6-10/No data
Plasma Protein Binding %
99
Volume Of Distribution L/Kg
0.2-0.7
Dose For Normal Renal Function
50-250 mg/m2
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: No data
References
Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet. 1987; 12: 223-52. [PMID: 3297462] / Sinkule JA. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology,pharmacokinetics, adverse effects and use as an antineoplastic agent. Pharmaco-therapy. 1984; 4: 61-73. [PMID: 6326063]